Summarize with ChatGPT
At-a-Glance: Key Takeaway
- The 2025 AUA Guideline on Male Chronic Pelvic Pain emphasizes non-invasive, multimodal care.
- Shockwave therapy (low-intensity ESWT) was reviewed and received a high level of evidence rating.
- Research suggests benefits for pain reduction, urinary function, and sexual health in CPPS and chronic prostatitis.
- SoftWave provides a non-invasive technology option that can be integrated into guideline-aligned care.
- Guidelines highlight the value of combining therapies such as PT, lifestyle strategies, and behavioral support.
Why the 2025 AUA Guideline Matters
The American Urological Association (AUA) has updated its guidelines for Male Chronic Pelvic Pain, covering Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CPPS), Chronic Scrotal Content Pain (CSCP), and related conditions such as hard flaccid syndrome.
The guideline provides clarity on:
- Comprehensive evaluation: assess pelvic floor myalgia, psychosocial factors, and overlapping conditions before labeling CPPS.
- First-line care: emphasize non-invasive, multimodal therapies such as pelvic floor PT, lifestyle changes, and behavioral support.
- Evidence review: low-intensity shockwave therapy (Li-ESWT) was supported by multiple randomized controlled trials (RCTs) and earned a high-grade evidence rating.
Evidence for Shockwave Therapy in CPPS
Published RCTs of Li-ESWT suggest improvements in:
- Pain and discomfort
- Urinary function
- Sexual function
- Overall quality of life
This marks a clear shift. Shockwave therapy, once considered experimental, is now recognized as an evidence-supported tool within multimodal care.
Why Urologists, PTs, GPs, and Pelvic Health Providers Are Considering SoftWave
Stay in Step with Guidelines
The AUA highlights multimodal, non-invasive strategies. SoftWave provides a technology option that can be aligned with these recommendations.
For Patients Who Need More Options
Not all patients improve with antibiotics, medications, or PT alone. SoftWave expands the range of non-invasive choices available to providers building comprehensive care plans.
Complement, Don’t Replace
SoftWave is designed to complement pelvic floor therapy, lifestyle interventions, and behavioral support. It may help optimize outcomes while integrating seamlessly into existing protocols.
Evidence-Informed Conversations
Li-ESWT has been evaluated in multiple RCTs and reviewed in the 2025 guideline. Providers can reference this evidence base when discussing emerging, non-invasive therapies with patients.
Practice Differentiation
Offering SoftWave can help clinics position themselves as early adopters of evidence-informed care for pelvic pain and prostatitis.
Perspectives from Experts
- Holly Tanner, PT — SoftWave provider and contributor to AUA guideline research, highlights how pelvic health providers can integrate shockwave into multimodal care. 👉 Watch Holly Tanner’s video
- Dr. Rachel Rubin, MD — SoftWave provider and leading sexual medicine expert, shares observations on how these guidelines expand patient-centered options.
👉 Watch Dr. Rachel Rubin’s video
The SoftWave Advantage
SoftWave’s patented broad-focused applicator delivers energy to both superficial and deep tissues, supporting local circulation and tissue activation. These biologic effects align with the non-invasive, multimodal strategies emphasized in the new AUA guidelines.
For patients who have not achieved results with conventional therapies, providers may consider SoftWave as a non-invasive option within a multimodal care approach.
Why This Matters for Your Practice
- Urologists: Stay guideline-aligned while offering additional non-invasive options.
- Pelvic Health PTs: Pair SoftWave with hands-on therapy for deeper, more effective care.
- General Practitioners (GPs): Gain clarity on referral pathways for patients struggling with CPPS or chronic prostatitis.
- Pelvic Health Specialists: Differentiate your clinic with an option supported by published ESWT studies and AUA review.
👉 Learn more SoftWave Pelvic Health & AUA Guidelines